8-K: Alzamend Neuro Issues Warrants for Common Stock Purchase in Exchange Agreement with Orchid Finance LLC

Alzamend Neuro enters into an agreement with Orchid Finance LLC, issuing warrants to purchase one million shares of common stock as part of a securities purchase and exchange agreement.

Summary

• Alzamend Neuro, Inc. has entered into a Securities Purchase & Exchange Agreement with Orchid Finance LLC.
• The agreement involves exchanging Orchid Finance's Series A Convertible Preferred Stock for Alzamend's Series C Convertible Preferred Stock.
• Alzamend will sell up to 500 shares of Series C Convertible Preferred Stock and warrants to Orchid Finance for up to $5,000,000, less a 5% discount.
• The initial tranche includes warrants to purchase 1,000,000 shares of Common Stock, with Orchid Finance cancelling warrants for 640,000 shares.
• Subsequent tranches are scheduled monthly, contingent on the average closing price of the Common Stock being at or above $0.10.
• The agreement includes provisions for preferential rights and rights of first refusal for Orchid Finance in future financings.
• Each share of Series C Preferred Stock has a stated value of $10,000 and is convertible into Common Stock at a price no lower than $0.10.
• Holders of Series C Preferred Stock are entitled to cumulative cash dividends at an annual rate of 15%.
• The warrants have an exercise price of $0.92125 and expire five years from the Execution Date.
• The company may not issue more than 19.99% of the total shares of Common Stock without stockholder approval.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The agreement provides the company with needed capital, but also introduces potential dilution and restrictions.

Positives

• The agreement provides Alzamend Neuro with up to $5,000,000 in financing.
• Cancellation of existing warrants reduces potential dilution from 640,000 shares.
• The agreement includes provisions for preferential rights and rights of first refusal for Orchid Finance in future financings, potentially attracting further investment.

Negatives

• The issuance of warrants and convertible preferred stock could lead to significant dilution of existing shareholders.
• The company is restricted from issuing more than 19.99% of the total shares of Common Stock without stockholder approval.
• The company is subject to potential penalties if it fails to meet certain deadlines related to the registration statement.

Risks

• The company may not be able to obtain stockholder approval for the issuance of shares exceeding 19.99% of the total shares of Common Stock.
• The average closing price of the Common Stock may not be equal to or greater than the Floor Price, delaying subsequent tranches.
• The company may be subject to penalties if it fails to meet certain deadlines related to the registration statement.
• The company's stock price could be negatively impacted by the potential dilution from the issuance of warrants and convertible preferred stock.

Future Outlook

The company anticipates receiving up to $5,000,000 in financing through the sale of Series C Preferred Stock and warrants, contingent on meeting certain conditions and obtaining regulatory and stockholder approvals.

Industry Context

This announcement reflects a common financing strategy for small-cap companies, utilizing convertible securities and warrants to raise capital. The specific terms, such as the conversion price and dividend rate, are tailored to the company's financial situation and the investor's risk appetite.

Comparison to Industry Standards

• The use of convertible preferred stock and warrants is a common financing technique, especially for companies in the biotechnology and pharmaceutical sectors.
• Comparable companies like Novavax and Sorrento Therapeutics have used similar instruments to raise capital.
• The 15% dividend rate on the Series C Preferred Stock is relatively high, reflecting the risk associated with investing in a company like Alzamend Neuro.
• The warrant exercise price of $0.92125 is also a key factor, as it determines the potential return for Orchid Finance and the dilution for existing shareholders.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of warrants and convertible preferred stock.
• The company's employees and operations will benefit from the additional capital.
• The company's creditors may be impacted by the new financing and its terms.

Next Steps

• Alzamend Neuro must file a proxy statement to obtain stockholder approval for the issuance of shares exceeding 19.99% of the total shares of Common Stock.
• The company must file a registration statement covering the resale of the Conversion Shares and the Warrant Shares.
• The company must secure the listing or designation for quotation of all of the Conversion Shares and the Warrant Shares.

Key Dates